Industry Spotlight Session 10+12

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disease characterized by complement-mediated thrombotic microangiopathy, with significant implications for kidney health. Despite advances in understanding, the clinical presentation and management of aHUS remains complex, particularly in cases associated with triggers such as pregnancy or autoimmune conditions.

This spotlight session, chaired by Prof. Shoichi Maruyama (Nagoya University, Japan) will begin with a concise yet comprehensive overview of aHUS, including global perspectives on current management approaches. Dr. Anuja Java (Washington University in St. Louis, US) will then explore the clinical picture of aHUS, including pathophysiology and the role of the complement system, diagnostic challenges, and evolving treatment paradigms. Finally, Prof. Wai Lim (Sir Charles Gairdner Hospital, Australia) will discuss recent guidance for managing aHUS associated with clinical triggers, drawing on both multidisciplinary recommendations and regional insights.

The session will conclude with an interactive Q&A, offering delegates the opportunity to engage directly with the faculty and discuss practical strategies for optimizing patient care. This session will deliver valuable insights and ignite further interest in the evolving landscape of aHUS management.

1. Identify key clinical and genetic features of atypical hemolytic uremic syndrome (aHUS), and recognize how complement dysregulation contributes to disease pathogenesis

2. Understand current diagnostic and management strategies for aHUS, including approaches for cases associated with triggers such as pregnancy and autoimmune conditions

3. Explore how to integrate recent multidisciplinary guidance and regional recommendations into clinical practice to optimize outcomes for patients with aHUS